| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_587d32d5e58cdcbf9cef902174eaa73d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c394b038e6ea703aea043d3e22ac5c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4ea5203c7c94a36da317f4e3ec368490
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_459c810b63d0146cd585f7779cdf8836 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-51 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0775 |
| filingDate |
2012-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1821798c823bf30ef33d3c14668ba78d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc1fd0b1771f872e1040e4cab75f690a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f4344cd06351ce72812ab9edaa31785
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_969abca3ca1a2cb0db5a808ac731ce1d |
| publicationDate |
2013-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013089565-A1 |
| titleOfInvention |
Immune privileged and modulatory progenitor cells |
| abstract |
Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also emply soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like. |
| priorityDate |
2006-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |